Key clinical point: Intermediate-to-high risk HER2-negative early breast cancer can be treated with an anthracycline-free regimen.
Major finding: Five-year DFS rates were 89.6% with TC vs. 89.9% with EC-T.
Study details: Randomized clinical trial of 2,449 women with early HER2-negative early breast cancer.
Disclosures: Genomic Health, Sanofi, and Amgen supported the study. Dr. Nitz and multiple coauthors disclosed financial relationships with these companies and others.
Nitz U et al. J Clin Oncol. 2019 Feb 20. doi: 10.1200/JCO.18.00028.